All You Need to Know About Invega Sustenna Prescribing Information

Introduction

Prescribing medication to patients requires diligence and awareness on the part of the healthcare provider. Invega Sustenna is one such medication that has gained popularity among doctors for treating schizophrenia. This article aims to provide comprehensive information on prescribing Invega Sustenna, including its indication, dosing, administration, and adverse effects.

Overview of Invega Sustenna

Invega Sustenna is an antipsychotic medication that contains paliperidone palmitate. It is approved by the FDA for the treatment of schizophrenia in adults. Invega Sustenna is a long-acting injectable formulation that is administered once a month. Paliperidone, the active ingredient in Invega Sustenna, is a metabolite of risperidone, which is another antipsychotic medication.

Indications

Invega Sustenna is indicated for the treatment of schizophrenia in adults. Schizophrenia is a chronic mental illness that affects a person’s ability to think, feel and behave clearly. The symptoms of schizophrenia include delusions, hallucinations, disordered thinking, and abnormal behaviors. Invega Sustenna helps control these symptoms and improve the patient’s quality of life.

Dosing

Invega Sustenna is available in three dosages, 39 mg, 78 mg, and 156 mg. The recommended initial dose is 234 mg, which is administered on day one, followed by 156 mg on day eight. After that, the patient receives 39-156 mg of Invega Sustenna monthly. The healthcare provider should adjust the dosage based on the patient’s response and tolerability.

Administration

Invega Sustenna is administered as a deep intramuscular injection in the deltoid or gluteal muscle by a healthcare professional. The injection site should be rotated to prevent injection site reactions. The patient should undergo a test dose before the first injection to check for hypersensitivity.

Adverse Effects

Like all medications, Invega Sustenna has some adverse effects that healthcare providers should be aware of. The most common adverse effects are injection site reactions, which include pain, redness, and swelling. Other adverse effects include weight gain, sedation, akathisia (restlessness), orthostatic hypotension (low blood pressure when standing up), and EPS (extrapyramidal symptoms) such as dystonia, akinesia, and rigidity.

Conclusion

Invega Sustenna is a valuable medication for treating schizophrenia in adults and has been proven to be effective in controlling symptoms. Healthcare providers should be aware of Invega Sustenna’s indications, dosing, administration, and adverse effects when prescribing it to their patients. It is essential to educate patients about the medication to improve adherence and ensure the best outcome.

Speech tips:

Please note that any statements involving politics will not be approved.